GD2 targeting by dinutuximab beta is a promising immunotherapeutic approach against malignant glioma.
J Neurooncol
; 147(3): 577-585, 2020 May.
Article
in En
| MEDLINE
| ID: mdl-32246395
Key words
Full text:
1
Collection:
01-internacional
Database:
MEDLINE
Main subject:
Brain Neoplasms
/
Gangliosides
/
Glioma
/
Immunotherapy
/
Antibodies, Monoclonal
/
Antineoplastic Agents
Limits:
Humans
Language:
En
Journal:
J Neurooncol
Year:
2020
Type:
Article
Affiliation country:
Germany